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Abstract Osteoporosis is defined simply as ‘‘a skeletal
disorder characterized by compromised bone strength
predisposing to an increased risk of fracture. Thus, any
bone lesion that causes fragility fracture is osteoporosis,
which has quite heterogeneous backgrounds. Chronic kid-
ney disease-related bone and mineral disease (CKD-MBD)
is defined as ‘‘a systemic disorder of mineral and bone
metabolism due to CKD, which is manifested by abnor-
malities in bone and mineral metabolism and/or extra-
skeletal calcification’’. Although CKD-MBD is one of the
possible causes of osteoporosis, we do not have evidences
that CKD-MBD is the only or crucial determinant of bone
mechanical strength in CKD patients. The risk of hip
fracture is considerably high in CKD patients. Drugs that
intervene in systemic mineral metabolism, indeed, lead to
the improvement on bone histology in CKD patients.
However, it remains unclear whether the intervention in
systemic mineral metabolism also improves bone strength,
today. Thus, the use of drugs that directly act on bone and
the introduction of fracture liaison concept are promising
strategies for fragility fracture prevention among CKD
patients, as well as treatment for CKD-MBD.
Keywords Fragility fracture  Osteoporosis  Chronic
kidney disease-related bone and mineral disease (CKD-
MBD)  Fracture liaison
Introduction
Various pathological conditions are found in bone among
patients with chronic kidney disease (CKD), and the
pathophysiological mechanisms that underlie these lesions
are also complicated. Here, I briefly review the present
condition of fragility bone fracture and its treatment in
CKD patients.
Osteoporosis and CKD-MBD
Osteoporosis is defined by the World Health Organization
as ‘‘a skeletal disorder characterized by compromised bone
strength predisposing to an increased risk of fracture’’ [1].
This definition omits the following, which had been
included in the previous definition [2]; ‘‘low bone mass’’
and ‘‘microarchitectural deterioration of bone tissue’’. The
revision clearly indicates that the latter conditions are no
longer a requirement or a sufficient condition of osteo-
porosis. In other words, any bone condition that causes
fragility fracture is now considered as osteoporosis. How-
ever, the disease definition is frequently misunderstood,
because bone mass measurement is still the standard
method to diagnose osteoporosis. Although osteoporosis is
a disease characterized by compromised bone strength,
there is no practical tool to monitor bone mechanical
strength at bedside, today. Bone mass is, indeed, a strong
determinant of bone mechanical strength [3]; bone mass is
used as a diagnosing tool for osteoporosis under the pre-
mise that extremely low bone mass could be regarded as a
sufficient condition of compromised bone strength.
Since low bone mass is neither a requirement nor a
sufficient condition of compromised bone strength, a cur-
rent diagnosis of osteoporosis is quite inaccurate, which
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could lead to both false-negative and false-positive cases.
Yet, we do not have any other practical tools that indicate
bone strength, with the exception of a patient’s medical
history. Thus, bone mass measurement is considered the
most powerful tool available today to diagnose
osteoporosis.
However, bone mass is not the only determining factor
of bone mechanical strength. Factors other than bone mass
that determine bone mechanical strength are generally
considered aspects of ‘‘bone quality’’ [4]. It has often been
said that ‘‘bone mechanical strength is predominantly
prescribed by bone mass, and bone quality contributes’’,
which seems to be true in most of the cases, but not all the
cases. For example, bone mineral density is generally low
in elementally school children, and although they fall quite
often, they seldom suffer from fragility fractures. Thus,
bone quality is sometimes likely to be a more important
factor than bone mass for preventing fragility fracture, at
least in some patient populations. At present, the ratio of
importance of bone mass and bone quality is not clear.
A primary reason for this is that it is difficult to define
bone mechanical strength. Because the risk of fragility
fracture incidence is also dependent on the risk of fall, it
does not strictly represent bone mechanical strength. In
ex vivo destruction studies using extracted bone samples,
different results will be obtained based on the direction or
moment of force applied to the samples. Moreover, bone
hardness and viscoelastic properties are different charac-
teristics that contribute independently to the resistance
against destruction [5]. Thus, osteoporosis is a heteroge-
neous disease condition in that many factors contribute to
bone fragility with different proportions in each case. The
disease background is also quite heterogeneous.
Chronic kidney disease-related bone and mineral disease
(CKD-MBD) is defined by the Kidney Disease: Improving
Global Outcomes as ‘‘a systemic disorder of mineral and
bone metabolism due to CKD, which is manifested by
abnormalities in bone and mineral metabolism and/or
extra-skeletal calcification’’ [6]. CKD-MBD is a disease
consisting of three inter-related components: abnormal
laboratory examination results including parathyroid dys-
functions, bone metabolic abnormalities and abnormal soft
tissue calcification including vascular calcification. At one
time, the term ‘‘renal osteodystrophy (ROD)’’ indicated a
disease condition similar to CKD-MBD, but it is now
considered simply a pathomorphological feature that indi-
cates bone lesions associated with CKD-MBD [7].
According to the definition of CKD-MBD, bone lesions
caused by abnormalities in systemic mineral metabolism
associated with CKD are partial features of CKD-MBD,
but those lesions do not have to be accompanied by the
deterioration of bone mechanical strength. Bone disease
with deteriorated mechanical strength is osteoporosis, and
CKD-MBD is one of the possible causative backgrounds of
osteoporosis (Fig. 1). However, even in those cases in
which CKD-MBD has some roles in the deterioration of
bone strength, other factors could also simultaneously
contribute to the development of osteoporosis, as osteo-
porosis has quite heterogeneous backgrounds. We previ-
ously advocated a disease concept termed ‘‘uremic
osteoporosis’’ that is caused by uremic toxins but not
abnormal mineral metabolism [8]. Although many studies
are required before understanding this disease condition in
detail, it is certain that there are various backgrounds lying
behind the bone fragility among patients with CKD. It is,
thus, a leap of logic to conclude that CKD-MBD is the only
or crucial determinant of bone mechanical strength in CKD
patients.
Bone fracture in CKD patients
It has been confirmed that the hip fracture (HFx) risk is
considerably high in dialysis patients in many countries
[9–11] including Japan [12]. The risk is 4–13 times higher
in dialysis patients compared to the general population.
The risk tends to be higher in high-latitude regions in the
United States [13]. In Japan, the risk is higher in western
prefectures [14], indicating that sunlight has little to do
with the HFx risk. Although many investigators consider
that the risk is also higher in predialysis CKD patients
[15, 16], an opposing view has been reported [17]. A few
reports contended that the risk of spinal compression
fracture is also high in dialysis patients [18].
osteoporosis fall






Fig. 1 The pathophysiological mechanism of fragility fracture in
CKD patients. Direct cause of fragility fracture is osteoporosis.
Generally, the major cause of osteoporosis is osteopenia, and
osteopenia is common in CKD patients. Uremia is likely to
deteriorate bone material properties. According to the disease
concept, bone fragility is not the requirement of CKD-MBD.
However, CKD-MBD has a potential to cause osteoporosis. The
frequency of the fall is another major risk of fragility fracture, and
uremia also increases the risk of fall
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Falls are common in especially elder CKD patients [19],
which is very likely to be one of the major causes of ele-
vated HFx risk. Advanced muscle weakness [20], frailty
[21], and deteriorated cognition [22] are potential con-
tributors to elevated risk of falling among CKD patients.
The survival prognosis generally becomes poorer in
patients who have incurred a HFx, and this trend is more
evident in dialysis patients [23, 24]. Japanese dialysis
patients demonstrated relatively better life prognosis after
HFx [25]. However, FRAX, a tool to predict future fracture
risk, can predict the risk of mortality even in Japan [26].
It is difficult to know whether being at a high risk of
falling is the major cause of the elevated HFx risk in
dialysis patients. The majority of clinicians and clinical
researchers assume that bone mechanical properties are
also deteriorated among dialysis patients. If this assump-
tion is true, many dialysis patients are suffering from
osteoporosis.
What happens in bone when kidney is injured?
The kidney is a pivotal organ for systemic mineral meta-
bolism. When a patient’s kidney is injured, the systemic
mineral metabolism is affected and the function of bone,
which is another pivotal organ for systemic mineral
metabolism, is altered through the collapsed feedback
system. This is the general idea regarding the development
of bone lesions in CKD-MBD.
Among the many humoral factors affecting bone meta-
bolism in disease states, the largest influence is brought by
parathyroid hormone (PTH). PTH is secreted by parathy-
roid gland, which is hyperactivated under CKD conditions.
PTH promotes the activity of bone cells, namely osteo-
blasts, osteocytes and osteoclasts, at microscopic levels. In
macroscopic levels, PTH causes cortical thinning and
porosis [27] that could result in increased bone fragility. In
fact, elevated serum level of alkaline phosphatase, a likely
marker for accelerated bone metabolic activity, is reported
to be associated with a higher risk of HFx incidence [28].
However, a controversy still remains on the relationship
between parathyroid function and structure-related bone
strength [29, 30]. One possible explanation for this issue is
that extremely high plasma level of PTH is required to
cause evident cortical thinning in dialysis patients [31],
because skeletal resistance to PTH stimuli is increased in
uremic condition [32–34].
Bone condition that has shown an extremely low fre-
quency of bone remodeling, which is called ‘‘adynamic
bone’’ [35] is also observed in dialysis patients, presumably
due to increased skeletal resistance. Investigators have
speculated that in the adynamic bone condition, the bone
mechanical strength could be deteriorated through
accumulated microdamages [36]. However, the relation-
ship between bone fragility and each category of the classic
ROD classification (Fig. 2) remains unknown. This clas-
sification is dependent on bone metabolism but not bone
mechanical properties [37].
Treatment for hyperparathyroidism in CKD patients has
been greatly improved [38]. Recent clinical studies have
obtained controversial results regarding the relationship
between PTH and HFx risk [39–42]. The decreased inci-
dence of severe secondary hyperparathyroidism due to the
development of medical and surgical treatment seems to
have contributed to these unclear results. Moreover,
osteomalacia caused by the depositions of aluminum or
iron on a skeletal calcified front has been nearly eliminated
[43]. Thus, the contribution of CKD-MBD to the devel-
opment of bone fragility can be expected to have decreased
today compared to that in the 1980s. Yet, the HFx risk in
dialysis patients has remained extremely high, today. We
must, therefore, consider the effect of factors other than
CKD-MBD that may promote bone fragility in CKD
patients.
Bone mass is regarded as the most important and crucial
factor in the prediction of bone mechanical properties in
individuals with primary osteoporosis. Bone mass seems to
be a major determinant of bone strength among dialysis
patients also. In CKD patients, the bone mass starts to
decrease at the early predialysis period [44]. Abnormal
vitamin D metabolism, hypoproteinemia, treatments for
kidney disease, and parathyroid dysfunction are assumed to

















Fig. 2 Classic ROD classification. Histological findings of bone
samples obtained by bone biopsy are classified into 5 categories by
two assessing axes; bone cell activities and primary mineralization
speed. This classification is suitable to evaluate bone metabolic
condition in CKD patients because CKD patients demonstrate broad
spectrums in these two assessing axes. The logic of this classification
is obviously clearer than that of the turnover–mineralization–volume
classification, which was advocated subsequently to this classifica-
tion. However, the need of multifaceted information is recognized for
an assessment of bone, and bone histology alone is not capable to
meet the need, today. Histological findings obtained from bone
sections, in fact, give no information about bone biochemical or
mechanical properties, and only limited information about the
structural properties. Thus, bone biopsy is not almighty. Considering
it as the ‘‘gold standard’’ is an overvaluation
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CKD patients. By the time of dialysis initiation, an indi-
vidual’s bone mineral density is generally low, but the
bone mass may not decrease as fast as it did in the pre-
dialysis period. The promotion of osteoblast apoptosis was
shown to be a likely pathophysiological mechanism
through which severe hyperparathyroidism causes exten-
sive bone loss in dialysis patients [45], in addition to the
promotion of osteoclastic bone resorption. The clinical
significance of bone mass measurement using dual-energy
X-ray absorptiometry was not confirmed among dialysis
patients [46]. However, recent studies have revealed that
lower bone mass is associated with a higher fracture risk
even in dialysis patients [47, 48].
Many clinicians/clinical investigators have an impres-
sion that bone quality in dialysis patients is deteriorated,
although no clear evidence exists on this issue. Bone
structural properties that could decrease bone mechanical
strength are changed in dialysis patients [49]. In experi-
mental animal models, kidney injury caused the deterio-
ration of bone material properties [50]. In those animals, a
viscoelastic property of extracted long bones was deterio-
rated, and both the modification of type-I collagen with
advanced glycation end-products (AGE) and bone apatite
disorientation were significantly associated with the dete-
rioration [51]. The deterioration in bone material properties
was specifically observed in the uremic condition, but it
was not associated with abnormal mineral metabolism.
Therefore, strictly speaking, these bone abnormalities
cannot be regarded as a feature of CKD-MBD [8]. The
AGE-modified type-I collagen was also detected in bone
samples obtained from dialysis patients [52].
Fragility fracture prevention in CKD patients
The original reason for using anti-osteoporotic agents was
to strengthen bone mechanical properties, leading to a
reduction in the fracture risk. However, most of the exist-
ing anti-osteoporotic agents directly act on bone to increase
bone mass, and therefore, those drugs are referred to as
direct bone metabolic modulators in this manuscript. Bone
mass is generally low in CKD patients, and low bone mass
increases fracture risk. The use of direct bone metabolic
modulators that increase bone mass would, thus, seem to
have certain benefit for CKD patients. Although low bone
mass is neither a requirement nor a sufficient condition of
compromised bone strength, it is certain that increasing
bone mass strengthens the bone mechanical property, at
least to some extent.
There is a significant limitation regarding the use of
direct bone metabolic modulators in patients with kidney
dysfunction. Bisphosphonate, which is most commonly
applied for treatment against primary osteoporosis, is
eliminated through urinary extraction, and there is a risk of
bisphosphonate accumulating in bone when it is used for
dialysis patients [53]. Accumulated bisphosphonate in bone
has the potential to reduce viscoelastic properties [54],
which could increase the risk of atypical femoral fracture
[55–57]. Because bisphosphonate is highly selectively
distributed to bone tissue, it is difficult to monitor its
accumulation clinically.
Unlike bisphosphonate, the human monoclonal antibody
denosumab does not accumulate even in CKD patients.
However, its hypocalcemic action tends to be amplified in
CKD patients [58]. It must be in mind that hypocalcemia in
dialysis patients directly induces an aggravation of hyper-
parathyroidism [59]. Although teriparatide is, indeed,
effective in some dialysis patients, its vasodilative action
often compels a discontinuation of the treatment because it
can induce severe hypotension. Regarding the clinical
effect of selective estrogen receptor modulators in CKD
patients, no clear consensus has been established [60].
CKD-MBD is a consequence of abnormal systemic
mineral metabolism. Therefore, drugs that intervene in
systemic mineral metabolism are frequently used for a
CKD-MBD treatment. Vitamin D receptor activator
(VDRA) and calcimimetics may provide a decreased
fracture risk by suppressing hyperactivated parathyroid
function. These systemic mineral metabolism modulators
surely lead to a certain improvement in bone histology; in
other words, they change bone metabolism. However, the
accurate effects of these agents on bone mechanical prop-
erties are not yet verified. VDRA also demonstrates a local
action on bone. Long-acting VDRA, such as alfacalcidol
[61] or eldecalcitol [62] in particular, have the likely
potential to prevent fragility fracture through their own
direct actions on bone. A study conducted in the United
States indicated that the use of cinacalcet hydrochloride
decreased the fracture risk among dialysis patients [63] via
a yet unverified mechanism. VDRA and cinacalcet may
prevent fragility fracture through intervening in vitamin K
metabolism [64]. Further studies are required to elucidate
whether cinacalcet merely intervened in systemic mineral
metabolism or also acted directly on bone to provide the
decreased fracture risk.
PTH is a humoral factor that affects systemic mineral
metabolism; teriparatide was developed to promote bone
formation directly by the intermittent use. Yet, no con-
sensus has been established about the indication of teri-
paratide therapy among CKD patients. The indication may
not be confined to those with PTH levels lower than the
target range indicated by clinical practice guidelines,
because circulating PTH molecules are unlikely to perform
full function in CKD patients [65]. The risk of hospital-
ization due to any fracture among dialysis patients was
approximately 30% lower in the patients treated with an
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angiotensin-converting-enzyme inhibitor or AT-1 receptor
blocker (Renin–Angiotensin–Aldosterone System inhi-
bitor, RAASi) among dialysis patients [66]. Such a phe-
nomenon has not yet been confirmed in a non-CKD
population. If bone material properties are truly deterio-
rated in CKD patients, it is possible that RAASi affect bone
material properties by preventing oxidation stress. The
serum concentration of bicarbonate ion has a significant
relationship with fracture risk [67].
Most of the drugs have more or less both aspects of
direct bone metabolism modulator and systemic mineral
metabolism modulator (Fig. 3). Although systemic mineral
metabolism modulators have been mainly prescribed to
CKD patients, the use of direct bone metabolic modulators
will be increased in near future from a perspective of fra-
gility fracture prevention.
Most fragility fractures occur due to a fall. The pre-
vention of falls is, thus, another important strategy in fra-
gility fracture prevention, and in fact, it is the most
practical tactic at this moment. The so-called fracture
liaison concept [68, 69] is now gaining attention as an
effective tool to prevent fragility fractures among the
elderly. Similar attempts should be made for fracture pre-
vention among CKD patients, especially dialysis patients.
Conclusion
‘‘Osteoporosis is a more severe form of osteopenia’’. ‘‘The
bone abnormality observed in CKD patients is CKD-MBD,
but not osteoporosis’’. ‘‘Aggressive treatment for CKD-
MBD is the major strategy for reducing the fragility frac-
ture risk in CKD patients’’. A close examination of these
statements suggests the conclusion that the above propo-
sitions are not logically true. However, many clinicians and
clinical researchers still seem to believe them [70, 71].
Incorrect assumptions hamper the development and spread
of useful treatment by providing meaningless research
questions and misleading the interpretation of the evi-
dences obtained. We must deal with fragility fracture
prevention among CKD patients with a flexible and logical
way of thinking.
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